Get the Stockscreener App
12.97
0.71%
-0.16
Xencor Inc stock is traded at $12.97, with a volume of 114.83K.
It is down -0.71% in the last 24 hours and down -19.97% over the past month.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
See More
Previous Close:
$13.13
Open:
$13.23
24h Volume:
114.83K
Relative Volume:
0.20
Market Cap:
$927.63M
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-4.4879
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
-5.87%
1M Performance:
-19.97%
6M Performance:
-39.28%
1Y Performance:
-44.19%
1-Day Range:
$12.98
$13.52
1-Week Range:
$12.98
$14.02
52-Week Range:
$12.98
$27.24
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
13.03 | 927.63M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.64 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
679.40 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.62 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.21 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.80 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Xencor’s EVP Nancy Valente sells $34,876 in stock By Investing.com - Investing.com Canada
Antibody Humanization Market Critical Analysis with Expert Opinion: Genentech, Adimab, Xencor - openPR
Xencor’s SVP sells $78,047 in stock By Investing.com - Investing.com Canada
Xencor’s SVP sells $78,047 in stock - Investing.com
Xencor Sr. vice president sells $131,851 in shares - Investing.com India
Xencor’s EVP Nancy Valente sells $34,876 in stock - Investing.com
Xencor CEO Dahiyat sells $268,080 in common stock By Investing.com - Investing.com South Africa
Xencor CEO Dahiyat sells $268,080 in common stock - Investing.com India
Xencor Executives Sell Shares to Cover Taxes - TradingView
Xencor Sr. vice president sells $131,851 in shares By Investing.com - Investing.com UK
Xencor stock touches 52-week low at $13.2 amid market challenges By Investing.com - Investing.com South Africa
Xencor stock touches 52-week low at $13.2 amid market challenges - Investing.com India
Mutual of America Capital Management LLC Buys Shares of 10,600 Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor, Inc. to Host Earnings Call - ACCESS Newswire
Top Premarket Gainers -March 07, 2025 at 07:34 am EST - Marketscreener.com
Xencor (NASDAQ:XNCR) Upgraded by StockNews.com to “Hold” Rating - Defense World
How does Xencor Inc (XNCR) change from a tortoise to a hare? - SETE News
Xencor, Inc. (NASDAQ:XNCR) Stake Increased by Amalgamated Bank - Defense World
Xencor stock touches 52-week low at $14.16 amid market challenges - Investing.com
Examining the Potential Price Growth of Xencor Inc (XNCR) - Knox Daily
Xencor stock touches 52-week low at $14.16 amid market challenges By Investing.com - Investing.com South Africa
Xencor, Inc. (NASDAQ:XNCR) Receives $34.88 Consensus Target Price from Analysts - Defense World
(XNCR) Technical Data - Stock Traders Daily
Principal Financial Group Inc. Grows Stock Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Wells Fargo & Company Issues Pessimistic Forecast for Xencor (NASDAQ:XNCR) Stock Price - Defense World
Xencor, Inc. (NASDAQ:XNCR) Stake Raised by Rhumbline Advisers - Defense World
Sanctuary Advisors LLC Raises Position in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor (NASDAQ:XNCR) Posts Quarterly Earnings Results - MarketBeat
Promising Pipeline and Innovative Platforms Drive Buy Rating for Xencor - TipRanks
Xencor’s Strategic Advancements and Financial Strength Signal Positive Outlook - TipRanks
Xencor (NASDAQ:XNCR) Trading 7.8% Higher on Better-Than-Expected Earnings - MarketBeat
RBC Capital Adjusts Xencor Price Target to $32 From $34, Maintains OutperformSpeculative Risk Rating - Marketscreener.com
Wedbush Cuts Price Target on Xencor to $31 From $38, Keeps Outperform Rating -February 28, 2025 at 06:37 am EST - Marketscreener.com
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results - sharewise
Brokerages Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $34.88 - MarketBeat
Xencor (NASDAQ:XNCR) Rating Lowered to Sell at StockNews.com - Defense World
Xencor: Q4 Earnings Snapshot - The Advocate
StockNews.com Downgrades Xencor (NASDAQ:XNCR) to Sell - MarketBeat
Xencor Reports 2024 Financials and Clinical Progress - TipRanks
Xencor Inc earnings beat by $0.19, revenue topped estimates - Investing.com South Africa
Xencor (NASDAQ:XNCR) Hits New 1-Year LowHere's Why - MarketBeat
Xencor's Q4 Net Loss Widens, Revenue Rises -February 27, 2025 at 09:44 am EST - Marketscreener.com
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (XNCR) XENCOR INC. Reports Q4 Revenue $52.8M, vs. FactSet Est of $20.4M - Marketscreener.com
Xencor: Q4 Earnings Snapshot -February 27, 2025 at 08:16 am EST - Marketscreener.com
Xencor Inc SEC 10-K Report - TradingView
Xencor stock touches 52-week low at $15.27 amid market challenges - Investing.com Nigeria
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xencor Inc Stock (XNCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Eckert Celia | SVP, GENERAL COUNSEL |
Mar 10 '25 |
Sale |
13.60 |
5,740 |
78,047 |
63,507 |
| Desjarlais John R | SR. VICE PRESIDENT & CSO |
Mar 10 '25 |
Sale |
13.60 |
9,697 |
131,851 |
236,574 |
| Dahiyat Bassil I | PRESIDENT & CEO |
Mar 10 '25 |
Sale |
13.60 |
19,716 |
268,080 |
465,419 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):